StreetInsider.com News Articles

Form 8-K Summit Therapeutics Inc. For: Jun 10

Fri, 12 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26640882.html

Form 8-K Summit Therapeutics Inc. For: Jun 10

Fri, 12 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26640882.html

Form 4 Summit Therapeutics Inc. For: Jun 12 Filed by: Zanganeh Mahkam

Fri, 12 Jun 2026 14:35:00 -0400

si-local-file:///var/storage/secattach/20260612/26640145.html

Form 4 Summit Therapeutics Inc. For: Jun 12 Filed by: Zanganeh Mahkam

Fri, 12 Jun 2026 14:35:00 -0400

si-local-file:///var/storage/secattach/20260612/26640145.html

Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares

Fri, 12 Jun 2026 12:37:33 -0400

Summit Therapeutics Inc. (NASDAQ: SMMT) co-chief executive officer Robert Duggan acquired 3.81 million shares of common stock on June 12, 2026, at $13.12 per share, according to a Securities and Exchange Commission filing.

Following the transaction, Duggan directly owns 573.88 million shares of Summit Therapeutics. The purchase was coded as "P" in the filing, indicating a private purchase.

The filing also disclosed Duggan's indirect holdings through family trusts and relationships. These include 25.82 million shares held by the Mahkam Zanganeh Revocable Trust, with Duggan's spouse serving as trustee, and 10.2 million shares in the Shaun Zanganeh Irrevocable Trust, also with his spouse

Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares

Fri, 12 Jun 2026 12:37:33 -0400

Following the transaction, Duggan directly owns 573.88 million shares of Summit Therapeutics. The purchase was coded as "P" in the filing, indicating a private purchase.

Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares

Fri, 12 Jun 2026 12:37:33 -0400

Following the transaction, Duggan directly owns 573.88 million shares of Summit Therapeutics. The purchase was coded as "P" in the filing, indicating a private purchase.

Form 4 Summit Therapeutics Inc. For: Jun 12 Filed by: DUGGAN ROBERT W

Fri, 12 Jun 2026 12:29:00 -0400

si-local-file:///var/storage/secattach/20260612/26639669.html

Form 4 Summit Therapeutics Inc. For: Jun 12 Filed by: DUGGAN ROBERT W

Fri, 12 Jun 2026 12:29:00 -0400

si-local-file:///var/storage/secattach/20260612/26639669.html

Form 8-K Summit Therapeutics Inc. For: Jun 10

Thu, 11 Jun 2026 07:44:00 -0400

si-local-file:///var/storage/secattach/20260611/26632671.html

Form 8-K Summit Therapeutics Inc. For: Jun 10

Thu, 11 Jun 2026 07:44:00 -0400

si-local-file:///var/storage/secattach/20260611/26632671.html

Form 424B5 Summit Therapeutics Inc.

Wed, 10 Jun 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260610/26626039.html

Form 424B5 Summit Therapeutics Inc.

Wed, 10 Jun 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260610/26626039.html

Summit Therapeutics announces $500 million stock offering

Tue, 09 Jun 2026 16:47:14 -0400

Summit Therapeutics Inc. (NASDAQ: SMMT) announced it has commenced an underwritten public offering of $500 million in common stock shares. The biopharmaceutical company is offering all shares in the proposed offering.

Summit plans to grant underwriters a 30-day option to purchase up to an additional $75 million of shares at the public offering price, minus underwriting discounts and commissions. The company stated the offering is subject to market and other conditions, with no assurance regarding completion timing or final terms.

The company intends to use net proceeds from the offering, combined with existing cash and cash equivalents, to fund research and development

Summit Therapeutics announces $500 million stock offering

Tue, 09 Jun 2026 16:47:14 -0400

The company intends to use net proceeds from the offering, combined with existing cash and cash equivalents, to fund research and development

Summit Therapeutics announces $500 million stock offering

Tue, 09 Jun 2026 16:47:14 -0400

The company intends to use net proceeds from the offering, combined with existing cash and cash equivalents, to fund research and development

Summit Therapeutics announces $500 million stock offering

Tue, 09 Jun 2026 16:47:14 -0400

The company intends to use net proceeds from the offering, combined with existing cash and cash equivalents, to fund research and development

Summit Therapeutics announces $500 million stock offering

Tue, 09 Jun 2026 16:47:14 -0400

The company intends to use net proceeds from the offering, combined with existing cash and cash equivalents, to fund research and development

Summit Therapeutics announces $500 million stock offering

Tue, 09 Jun 2026 16:47:14 -0400

The company intends to use net proceeds from the offering, combined with existing cash and cash equivalents, to fund research and development

Summit Therapeutics Announces Proposed Public Offering of Common Stock